RE:RE:RE:RE:RE:RE:RE:spoke to fred..Let's not forget this passage from the PR of May 10th, entitled: "Prometic reports on its 2018 annual and special meeting of shareholders highlights":
“Prometic’s priority in 2018 is to close the gap between fundamental value created over the last years and the current share price which does not reflect all the corporate, clinical and operational milestones delivered. The road map to accomplishing that is based on the following corporate action plan:
· A financial framework that will enable success by prioritizing projects, spending proportionately and controlling cashflow;
· A robust action plan for the plasminogen BLA review process where a multi-disciplinary, integrated team will review the entire BLA resubmission with the help of an external group of consultants specialized in regulatory affairs support services;
· A human resources strategy that will focus on having the right people, with the right skills and capacity to deliver while focusing on managing growth;
· A business development strategy centered around partnership initiatives focused on maximizing value by providing financial resources, participation in upside value creation, providing additional resources to de-risk development programs while increasing Prometic's international reach; and
· The continuing advancement of late stage clinical assets with the ability to respond to significant medical needs.”